Compare Illumina, Inc. (ILMN) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs VF Corp — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while VF Corp trades at $14.78 (market cap $5.86B). The key difference: Illumina, Inc. is far larger — about 4.9× VF Corp's market cap, and VF Corp pays a 2.42% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | VFC | |
|---|---|---|
Market Cap | $28.96B | $5.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $21.55 |
52-Week Low | $91.00 | $11.79 |
Enterprise Value | $30.32B | $10.14B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
VFC trades at $14.99, up 1.63% on the day, with a bearish technical signal and mixed earnings. Recent Q1 2027 results missed EPS estimates, though revenue exceeded expectations. The company faces challenges with Vans brand performance and a CFO transition, but maintains a raised fiscal 2027 sales outlook. Cash flow trends show improvement in 2026, with net cash flow turning positive.
Outlook remains cautious due to weak consumer sentiment and brand-specific headwinds, but deleveraging progress and margin gains offer potential upside. Risks include persistent Vans drag and macro pressures. Analyst consensus is Hold with a $17.44 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
